AMAG Pharmaceuticals — Q2 2015 Earnings Presentation
30 slides from AMAG Pharmaceuticals's earnings presentation, Jul 23, 2015
Slide 1: AMAG Pharmaceuticals 2Q 2015 Financial Results
AMAG Pharmaceuticals 2Q 2015 Financial Results July 23, 2015
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. Any statements contained herein which do not describe historical facts, including among others, statements regarding AMAG’s posi
Slide 3: 2Q15 Earnings Call Agenda
2Q15 Earnings Call Agenda 2 Agenda 2Q15 Highlights and Recent Developments 2Q15 Results and Financial Update Commercial Performance Update Maternal Health Hematology/Oncology & Hospital Portfolio Expansion Update 2015 Goals and Closing Remarks Q&A Speakers: Bill Heiden, Chief Executive Officer Frank
Slide 4: 2Q15 Highlights and Recent Developments
2Q15 Highlights and Recent Developments Achieved record sales and profitability Net product sales of $84.7 MM driven by Makena (+58% vs. 2Q14)1 Non-GAAP adjusted EBITDA increased to $52.1 MM2 Progressed Makena lifecycle management program Continued execution of BD strategy to further expand portfoli
Slide 5: 2Q15 Results & Financial Update
2Q15 Results & Financial Update Frank Thomas, President & COO
Slide 6: 2Q15 Financial Highlights
2Q15 Financial Highlights1 Net Product Sales ($ MM) Non-GAAP Adjusted EBITDA1 ($ MM) Non-GAAP Diluted EPS1 ($/share) Makena drives significant increase in product sales Strong expense management leads to growing adjusted EBITDA and EPS $398.4 MM ending cash and investments balance Total net leverage
Slide 7: Strong Sales Performance
Strong Sales Performance 1 Unaudited. Pro forma Makena sales for each quarter of 2014. Makena product acquired in November 2014. 2Includes recognition of one-time, non-cash revenue of $33.6 million related to the full termination of AMAG’s ex-U.S. Feraheme marketing agreement with Takeda. ($ MM) 2Q1
Slide 8: 2Q15 Financial Summary GAAP to Non-GAAP Comparison
($ in millions, except per share data) 2Q15 (GAAP) Adjustments 2Q15 (Non-GAAP) Total revenues $123.9 ($33.6) $90.3 Cost of products sold 19.7 (16.5) 3.2 Gross margin 104.2 ($17.1) 87.1 Operating expenses 43.1 (8.1) 35.0 Operating income / Adjusted EBITDA 61.1 ($9.0) 52.1 Interest and other (9.8) 2.9
Slide 9: 2Q15 Share Reconciliation
2Q15 Share Reconciliation 1Represents difference between ‘if converted’ and ‘treasury stock’ method of accounting for convertible debt. (in millions) 2Q15 Weighted average basic shares outstanding 30.6 Employee equity incentive awards 1.8 Convertible notes 7.4 Warrants 3.4 GAAP diluted shares outsta
Slide 10: Maternal Health
Maternal Health Bill Heiden, CEO
Slide 11: Maternal Health Business
Maternal Health Business Makena The only FDA-approved therapy to reduce recurrent preterm birth in certain at-risk women, with big market potential Cord Blood Registry World’s largest stem cell collections and storage company Velo Option Option to acquire orphan drug candidate for the treatment of s
Slide 12: Acquisition of Cord Blood Registry
Complementary business that expands AMAG’s maternal health platform Large addressable market Favorable market conditions Strong strategic and commercial fit Combined, larger HCP sales force will drive accelerated product growth for Makena and CBR Brings to AMAG a direct-to-consumer expertise that of
Slide 13: Velo Option
Velo Option For the treatment of severe preeclampsia $10M option fee: Purchased exclusive right to acquire an orphan drug candidate In development for the treatment of severe preeclampsia Option exercisable at completion of Phase 2b/3a clinical trial Further expands and diversifies portfolio, streng
Slide 14: Makena product advertisement
se «24 2s FOR YOUR PATIENTS WHO ARE AT RISK FOR ANOTHER PRETERM BIRTH (<37 WEEKS) ey a @~>» . wae wp = =" JES COONTS >
Slide 15: Makena: Strong Market Share Growth
: Strong Market Share Growth Estimated market share2 based on 140,000 patients $1 billion market opportunity1 4 percentage point gain in market share 2Q15 over 1Q15 Compounded Hydroxyprogesterone caproate 38% Makena 32% Off-guidance 30%3 1 Based on 140,000 patients, >16 injections/patient and net re
Slide 16: Hematology / Oncology and Hospital
Hematology / Oncology and Hospital
Slide 17: Hematology/Oncology & Hospital Business
Hematology/Oncology & Hospital Business Feraheme Used for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease (CKD) 4.2MM Americans diagnosed and suffering from IDA Daily oral iron is first line therapy for most IDA patients Many patients fail oral iron therap
Slide 18: Feraheme: Educate in 2Q15, Grow in 2H15
: Educate in 2Q15, Grow in 2H15 2Q15 – Educate & Hold Educate physicians about new label Drive total IV iron market growth Realize benefits of pricing and contracting strategies 2H15 – Refocus on Growth Grow market share (hospital segment) Drive total IV iron market growth Realize benefits of pricin
Slide 19: Growth Opportunities: Increase Share of CKD Market and Plan for Label Expansion
Growth Opportunities: Increase share of ckd market & plan for label expansion ~30% 1AMAG estimates market opportunity using ~$600/gram. 2IMS Health Data. 3 If regulatory approval is pursued and received for IDA (non-CKD). Opportunity with broad IDA indication ~$600 MM / year (non-dialysis)3 (980,000
Slide 20: Portfolio Expansion
Portfolio Expansion
Slide 21: Transformative Growth
Transformative Growth 2013 Total Revenue $81 MM 2014 Total Revenue $124 MM 2015 Total Revenue Guidance $395-430 MM 2015 Estimated Pro Forma Product Sales1 +$500 MM 2013 Adjusted EBITDA Net Loss 2014 Adjusted EBITDA $14 MM 2015 Adjusted EBITDA Guidance $210-225 MM 2015 Est. Pro Forma Adjusted EBITDA1
Slide 22: Executing on Business Development Strategy
Strong Financial profile, management team & corporate infrastructure Executing on Business Development Strategy 23 Commercial and operational excellence allows for continued growth and diversification focused on high-value specialty segments FUTURE PRODUCT Maternal Health Hematology/Oncology, Hospit
Slide 23: 2015 Goals
2015 Goals building a high-growth specialty pharma company Drive significant sales growth across product portfolio Makena Feraheme MuGard Adjusted EBITDA margin on product sales in excess of 50% Continue to execute on brand expansion/extension plans Makena multi-pronged lifecycle management program,
Slide 24: AMAG Pharmaceuticals 2Q15 Financial Results
AMAG Pharmaceuticals 2Q15 Financial Results July 23, 2015
Slide 25: Appendix
AMAG Pharmaceuticals Appendix 2Q 2015 Financial Results July 23, 2015
Slide 26: GAAP to Non-GAAP Financials for the Three Months Ended June 30
27 GAAP to Non-GAAP Financials for the Three Months Ended June 30 AMAG Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations (unaudited, amounts in thousands, except per share data) Three Months Ended Three Months Ended June 30, 2015 June 30, 2014
Slide 27: GAAP to Non-GAAP Financials for the Six Months Ended June 30
28 GAAP to Non-GAAP Financials for the Six Months Ended June 30 AMAG Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations to Non-GAAP Statements of Operations (unaudited, amounts in thousands, except per share data) Six Months Ended Six Months Ended June 30, 2015 June 30, 2014 GAAP
Slide 28: GAAP to Non-GAAP Financials (cont.)
GAAP to non-GAAP Financials for the Three and Six Months Ended June 31 (cont.) 29 1 Eliminate non-cash revenue related to recognition of previously deferred revenue on Takeda agreement. 2 Eliminate the following: (i) non-cash step-up of inventory from purchase accounting (2015); (ii) amortization ex
Slide 29: Adjusted EBITDA and Cash Earnings Reconciliation 2015 Updated Guidance
Adjusted EBITDA and Cash Earnings Reconciliation 2015 Updated Guidance ($ in millions) 2015 Updated Guidance GAAP Net income (loss) $75 - $90 Depreciation & amortization of intangible assets $55 Interest expense, net $40 Provision for income taxes $35 EBITDA $205 - $220 Non-cash collaboration revenu
Slide 30: AMAG Pharmaceuticals 2Q15 Financial Results
AMAG Pharmaceuticals 2Q15 Financial Results July 23, 2015